|
|
|
23.02.26 - 09:51
|
XFRA: MWBMU - HANDELSUNTERBRECHUNG - TEIL 3 (XETRA)
|
|
|
US11259P1093
GB00BJQTGV64
PLIPOSA00010
PLICI0000010
US72815G1085
CA92537Y1043
SE0016802797
CA7480331072
SE0016843809
SE0015797873
CA89602T1012
PLGDVIS00018
AU0000157455
CA75103L3092
PLDGNST00012
CA02074J5017
US68235C2061
KYG2993S1066
JP3141600001
PLSFD0000013
JP3396000006
US82322J1079
IT0005499949
US8122152007
PLIMGPW00013
SE0004899474
SE0009920994
US15102K1007
CA3933801001
US7004021009
JP3966660007
GB00BVZNY531
GB00BNG59574
BE0974380124
AU0000134694
JP3480600000
JP3187000009
CY0103562118
PLBLKPC00014
CA6488301079
CNE100004JD2
IT0005442154
AU0000141533
US4652701065
GB00BMC2XX17
PLROCCA00013
SE0005676103
AU0000058943
GB00BF044593
AU0000129496
CNE100003FC4
PLSMFBC00016
CA75585H2063
MU0461N00015
CA5791761086
JP3548660004
JP3497400006
JP3896000001
CA57778R1001
CNE100006V73
JP3335410001
CA72583H1064
JP3880800002
KYG2163K1076
US0269481091
HK0000735800
PLAIRMK00017
PLFRENT00014
PLCRBON00018
AU0000177271
DK0061411964
CA3686501071
BMG916101576...
|
|
|
|
|
|
|
|
|
|
|
|
|
17.12.25 - 10:06
|
Rakovina Therapeutics Management to Attend Partnering Meetings During JPM Week, January in San Francisco, California (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, today announced that senior members of the Company's executive leadership will be in San Francisco, California during the week of the annual J.P. Morgan Healthcare Conference (January 12-16, 2026) for a series of meetings with potential partners and members of the investment community.In addition, members of the Rakovina team will participate in Fierce JPM Week as part of the week's broader industry programming.“JPM week brings together a broad cross-section of global biotech and pharma leaders, and it remains one of the most efficient windows of the year for high-quality, in-person partnering discussions,” said Jeffrey Bacha, executive chairman of Rakovina. “Given the interest in AI drug development and the excitement stemming from the Company\...
|
|
|
|
|
|
|
|
|
29.11.25 - 02:15
|
Rakovina Therapeutics Announces Debentureholder Approval of Debenture Extension, Expiry of Warrant Incentive Program (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV)(FSE: 7JO0) a biopharmaceutical company advancing cancer therapies through AI-enabled drug discovery, announces that further to its news release dated June 30, 2025, and in accordance with the terms of a debenture indenture (the “Indenture”) between the Company and Odyssey Trust Company as the debenture trustee (the “Debenture Trustee”) dated May 29, 2023, governing the 12.0% convertible debentures of the Company in the aggregate principal amount of $1,454,000.00 (the "Convertible Debentures"), holders (each, a "Debentureholder") representing at least 66 2/3% of the outstanding principal of the Convertible Debentures have consented to the extension of the maturity date of the Convertible Debentures from November 29, 2025 to January 28, 2026 (the “Extension”). The Extension was approved by way of a written consent dated November 28, 20...
|
|
|
|
|
|
|
18.11.25 - 10:03
|
Rakovina Therapeutics′ President & CSO to Present and Join Expert Panel at the 9th Annual DDR Inhibitors Summit (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV)(FSE: 7JO0) a biopharmaceutical company advancing cancer therapies through AI-enabled drug discovery, today announced that its President and Chief Scientific Officer, Prof. Mads Daugaard, has been invited to present and participate as a panelist at the 9th Annual DNA Damage Response (DDR) Inhibitors Summit, taking place January 27–29, 2026, in Boston, MA....
|
|
|
10.11.25 - 19:30
|
Rakovina Therapeutics to Present New Data Highlighting CNS-Penetrant ATR and PARP1 Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV)(FSE: 7JO0) a biopharmaceutical company advancing cancer therapies through AI-enabled drug discovery, today announced that new data will be presented in two posters at the Society for Neuro-Oncology (SNO) Annual Meeting, taking place November 19–23, 2025, in Honolulu, Hawaii.The presentations will highlight Rakovina's AI-driven programs to discover and develop next-generation DNA-damage response (DDR) inhibitors engineered for central nervous system (CNS) penetration, supporting the development of potential new treatment options for primary and metastatic brain cancers.Presentation Details:...
|
|
|
27.10.25 - 09:03
|
Rakovina Therapeutics Showcases Potent AI-Developed ATR Inhibitors with CNS Penetrance at AACR-NCI-EORTC International Conference (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV)(FSE: 7JO0) is pleased to announce the successful presentation of new data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October 23–27 in Boston, Massachusetts. The Company's poster, titled “Novel ATR inhibitors with CNS penetrance developed by artificial intelligence,” highlights promising results from its AI-driven kt-5000AI drug discovery program for Ataxia telangiectasia and Rad3-related protein serine/threonine kinase (ATR) inhibitors for cancer therapy....
|
|
|
|
|
04.09.25 - 10:03
|
Rakovina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-powered drug discovery, today announced that Executive Chairman, Jeffrey Bacha, and Chief Financial Officer, Dr. David Kideckel, will attend and present at the H.C. Wainwright 27th Annual Global Investment Conference, taking place September 8th-10th in New York City....
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
